Allogene Therapeutics
ALLO
79 hedge funds and large institutions have $1.67B invested in Allogene Therapeutics in 2018 Q4 according to their latest regulatory filings, with 79 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
5,600% more call options, than puts
Call options by funds: $912K | Put options by funds: $16K
51.6% more ownership
Funds ownership: 0% → 51.6% (+52%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$615M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$130M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$66.7M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$66.6M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$57.7M |
Top Sellers
ALLO Hedge Fund Activity: Q4 2018 in Review
79 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2018, worth a combined $1.67B.
Buyers outnumbered sellers: 79 funds opened new ALLO positions and 0 closed out — a net gain of 79 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TPG Group Holdings (SBS) Advisors, opening a new position worth an estimated $615M.
- 79 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $1.67B of Allogene Therapeutics stock for Q4 2018.
- 79 funds opened new Allogene Therapeutics positions in Q4 2018 and 0 closed out, a net change of +79 holders.
- The largest Allogene Therapeutics buyer in Q4 2018 was TPG Group Holdings (SBS) Advisors, an estimated $615M added.
Based on aggregated 13F filings for Q4 2018.